Showing 1 - 4 results of 4 for search 'Gabriella Moretti', query time: 0.03s Refine Results
  1. 1
    Real-World Clinical Outcomes of Ribociclib in Combination with a Non-Steroidal Aromatase Inhibitor and a Luteinizing Hormone-Releasing Hormone Agonist in Premenopausal HR+/HER2− Advanced Breast Cancer Patients: An Italian Managed Access Program

    Real-World Clinical Outcomes of Ribociclib in Combination with a Non-Steroidal Aromatase Inhibitor and a Luteinizing Hormone-Releasing Hormone Agonist in Premenopausal HR+/HER2− Ad... by Nicoletta Staropoli, Elena Geuna, Gaetana Rinaldi, Giancarlo Bisagni, Vieri Scotti, Giovanni Faggioni, Laura Vannini, Carlo Arcara, Gabriella Moretti, Marco Gunnellini, Luigi Coltelli, Francesco Verderame, Lorenzo Livi, Giuseppina Sanna, Donatella Grasso, Giulia Abbinante, Francesca Ragni

    Published 2022-09-01
    Get full text
    Article
  2. 2
    A CT-Based Radiomic Signature Can Be Prognostic for 10-Months Overall Survival in Metastatic Tumors Treated with Nivolumab: An Exploratory Study

    A CT-Based Radiomic Signature Can Be Prognostic for 10-Months Overall Survival in Metastatic Tumors Treated with Nivolumab: An Exploratory Study by Valentina D. A. Corino, Marco Bologna, Giuseppina Calareso, Lisa Licitra, Mariagrazia Ghi, Gaetana Rinaldi, Francesco Caponigro, Franco Morelli, Mario Airoldi, Giacomo Allegrini, Alessandra Cassano, Daris Ferrari, Aurora Mirabile, Alicia Tosoni, Danilo Galizia, Marco Merlano, Andrea Sponghini, Gabriella Moretti, Luca Mainardi, Paolo Bossi

    Published 2021-05-01
    Get full text
    Article
  3. 3
    An Inflammatory Signature to Predict the Clinical Benefit of First-Line Cetuximab Plus Platinum-Based Chemotherapy in Recurrent/Metastatic Head and Neck Cancer

    An Inflammatory Signature to Predict the Clinical Benefit of First-Line Cetuximab Plus Platinum-Based Chemotherapy in Recurrent/Metastatic Head and Neck Cancer by Stefano Cavalieri, Mara Serena Serafini, Andrea Carenzo, Silvana Canevari, Deborah Lenoci, Federico Pistore, Rosalba Miceli, Stefania Vecchio, Daris Ferrari, Cecilia Moro, Andrea Sponghini, Alessia Caldara, Maria Cossu Rocca, Simona Secondino, Gabriella Moretti, Nerina Denaro, Francesco Caponigro, Emanuela Vaccher, Gaetana Rinaldi, Francesco Ferraù, Paolo Bossi, Lisa Licitra, Loris De Cecco

    Published 2022-10-01
    Get full text
    Article
  4. 4
    Validation of the AJCC prognostic stage for HER2-positive breast cancer in the ShortHER trial

    Validation of the AJCC prognostic stage for HER2-positive breast cancer in the ShortHER trial by Maria Vittoria Dieci, Giancarlo Bisagni, Alba A. Brandes, Antonio Frassoldati, Luigi Cavanna, Francesco Giotta, Michele Aieta, Vittorio Gebbia, Antonino Musolino, Ornella Garrone, Michela Donadio, Anita Rimanti, Alessandra Beano, Claudio Zamagni, Hector Soto Parra, Federico Piacentini, Saverio Danese, Antonella Ferro, Katia Cagossi, Samanta Sarti, Anna Rita Gambaro, Sante Romito, Viviana Bazan, Laura Amaducci, Gabriella Moretti, Maria Pia Foschini, Sara Balduzzi, Roberto Vicini, Roberto D’Amico, Gaia Griguolo, Valentina Guarneri, Pier Franco Conte

    Published 2019-11-01
    Get full text
    Article

Search Tools: